Patents by Inventor Katherine J. KAYSER-BRICKER

Katherine J. KAYSER-BRICKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE
    Publication number: 20240408093
    Abstract: The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from GSPT1, Cyclin K, RBM23, RBM39, IKZF1, IKZF3, PLK1, CDK4 or CK1alpha which is linked to a moiety that binds to a target protein selected from KRAS, HER2, EGFR, androgen receptor protein, estrogen receptor protein, ALK, IDH1, FLT3, FGFR1, FGFR4, FGFR2, FGFR3, ERK1, ERK2, FGR, HER3 or HER4. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.
    Type: Application
    Filed: October 4, 2022
    Publication date: December 12, 2024
    Inventors: Samuel W. GERRITZ, Katherine J. KAYSER-BRICKER, Taavi NEKLESA, David E. PULEO, James John MOUSSEAU, Nilesh ZAWARE, Kyle J. EASTMAN
  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20230061891
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Application
    Filed: July 23, 2021
    Publication date: March 2, 2023
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot
  • INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X
    Publication number: 20230065368
    Abstract: The disclosure provides novel chemical compounds useful as inhibitors of ubiquitin specific peptidase 9X (USP9X). USP9X inhibiting compounds are useful in the treatment of disease and disorders associated with modulation of USP9X, such as cancer.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 2, 2023
    Inventors: Bruce FOLLOWS, Katherine J. KAYSER-BRICKER, Adam Charles TALBOT, Scot MENTE, Tatiana SHELEKHIN, Anna ERICSSON
  • INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X
    Publication number: 20220041597
    Abstract: FLT3-ITD and FLT3-TKD are the most frequent mutations in acute myeloid leukemia (AML) with the former associated with a poor prognosis. Here we show that inhibition of the deubiquitinase USP9X by its inhibitor WP1130 or EOAI3402143 (G9) induces apoptosis preferentially in cells transformed by these mutant kinases, including FLT3-ITD-positive AML cell line MV4-11 and primary AML cells. Mechanistically, WP1130 induced aggresomal translocation of the mutant kinases, particularly FLT3-ITD in its activated and autophosphorylated conformation, to block the downstream signaling events, which was aggravated by knock down of USP9X. Moreover, USP9X physically associated with FLT3-ITD to inhibit its K63-linked polyubiquitination, while FLT3-ITD induced tyrosine phosphorylation and degradation of USP9X through the ubiquitin/proteasome pathway.
    Type: Application
    Filed: December 26, 2019
    Publication date: February 10, 2022
    Inventors: Bruce Follows, Adam Charles Talbot, Scot Mente, Sabine Ruppel, Tatiana Shelekhin, Katherine J. Kayser-Bricker
  • INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X
    Publication number: 20210346356
    Abstract: This disclosure provides methods of treating cancer with an inhibitor of ubiquitin specific peptidase 9X alone or in combination with an immune checkpoint pathway inhibitor.
    Type: Application
    Filed: September 19, 2019
    Publication date: November 11, 2021
    Inventors: Maureen LYNES, Weiping WANG, Bruce FOLLOWS, Katherine J. KAYSER-BRICKER, Adam Charles TALBOT, Scot MENTE, Tatiana SHELEKHIN, Anna ERICSSON
  • Tetrahydroquinoline compositions as BET bromodomain inhibitors
    Patent number: 11111229
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: September 7, 2021
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot
  • Benzopiperazine compositions as BET bromodomain inhibitors
    Patent number: 11084831
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: August 10, 2021
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20200369642
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Application
    Filed: January 28, 2020
    Publication date: November 26, 2020
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot
  • Phosphatase Binding Compounds and Methods of Using Same
    Publication number: 20200268897
    Abstract: The present invention provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Such target proteins can be any protein involved in the pathway of a disease or disorder, such as but not limited to cancer, neurodegeneration, metabolic disease, diabetes, insulin resistance, and so forth.
    Type: Application
    Filed: January 8, 2020
    Publication date: August 27, 2020
    Inventors: Craig Crews, Samuel W. Gerritz, Kyle J. Eastman, Katherine J. Kayser-Bricker, Jinshan M. Chen, David E. Puleo
  • Benzopiperazine compositions as BET bromodomain inhibitors
    Patent number: 10703764
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: July 7, 2020
    Assignee: Forma Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
  • Tetrahydroquinoline compositions as bet bromodomain inhibitors
    Patent number: 10611750
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 7, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot
  • BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20190330233
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Application
    Filed: June 18, 2019
    Publication date: October 31, 2019
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot, Mark J. Tebbe
  • Benzopiperazine compositions as BET bromodomain inhibitors
    Patent number: 10377769
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: August 13, 2019
    Assignee: Forma Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
  • Tetrahydroquinoline compositions as BET bromodomain inhibitors
    Patent number: 10336722
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: July 2, 2019
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot
  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20190127347
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot
  • BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20180312524
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Application
    Filed: July 6, 2018
    Publication date: November 1, 2018
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot, Mark J. Tebbe
  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20180215766
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Application
    Filed: March 27, 2018
    Publication date: August 2, 2018
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot
  • BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20160257699
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Inventors: Kenneth W. BAIR, Torsten HERBERTZ, Goss S. KAUFFMAN, Katherine J. KAYSER-BRICKER, George P. LUKE, Matthew W. MARTIN, David S. MILLAN, Shawn E.R. SCHILLER, Adam C. TALBOT, Mark J. TEBBE
  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20160256448
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Inventors: Kenneth W. BAIR, Torsten HERBERTZ, Goss S. KAUFFMAN, Katherine J. KAYSER-BRICKER, George P. LUKE, Matthew W. MARTIN, David S. MILLAN, Shawn E.R. SCHILLER, Adam C. TALBOT
  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20160257692
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Inventors: Kenneth W. BAIR, Torsten HERBERTZ, Goss S. KAUFFMAN, Katherine J. KAYSER-BRICKER, George P. LUKE, Matthew W. MARTIN, David S. MILLAN, Shawn E.R. SCHILLER, Adam C. TALBOT